The Lancet

The Lancet

Publication
0 followers

Leading medical journal with videos on clinical research, global health, and technology-enabled care and diagnostics discussion.

[Comment] Pimicotinib: A New Agent for an Orphan Disease
NewsMar 5, 2026

[Comment] Pimicotinib: A New Agent for an Orphan Disease

Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm driven by CSF‑1 over‑expression. The phase 3 MANEUVER trial evaluated pimicotinib, a selective CSF1R kinase inhibitor, against placebo in patients with inoperable or relapsed diffuse‑type TGCT. Results demonstrated statistically significant...

By The Lancet
[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing
NewsMar 5, 2026

[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing

The White House briefing on Sept 22 2025 linking prenatal acetaminophen to autism and promoting leucovorin was followed by an interrupted‑time‑series analysis of the Epic Cosmos database. Emergency‑department orders for paracetamol among pregnant women fell 10% (OER 0.90) while use among non‑pregnant women showed...

By The Lancet
[Viewpoint] Health Justice
NewsMar 3, 2026

[Viewpoint] Health Justice

The viewpoint piece separates health justice from the more commonly discussed health equity, arguing that the two concepts are often mistakenly merged. It highlights how decades of research on social determinants have produced a flood of studies documenting health gradients...

By The Lancet
[Comment] Considerations for Improving Non-Inferiority Trials
NewsMar 3, 2026

[Comment] Considerations for Improving Non-Inferiority Trials

Non‑inferiority trials are increasingly employed to evaluate new therapies that may offer advantages beyond efficacy, such as safety or convenience. However, their design and analysis present unique methodological challenges that can compromise study validity. The commentary outlines essential considerations, including...

By The Lancet
[Review] Autosomal Dominant Polycystic Kidney Disease
NewsFeb 27, 2026

[Review] Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) remains the most common hereditary cause of chronic kidney disease, imposing substantial morbidity, mortality, and healthcare costs worldwide. Recent advances in molecular genetics and high‑resolution imaging have sharpened diagnostic criteria and enabled more accurate...

By The Lancet
[Correspondence] The Need for Improved Sexual Health Among Survivors of Sex Trafficking
NewsFeb 27, 2026

[Correspondence] The Need for Improved Sexual Health Among Survivors of Sex Trafficking

The correspondence underscores a critical gap in sexual‑health care for survivors of sex trafficking, who experience STI rates 22‑111 times higher than the general population and elevated pregnancy and abortion risks. It advocates for decentralized, trauma‑informed services—including at‑home STI kits,...

By The Lancet
[Comment] Safeguarding Genomic Integrity in Pluripotent Stem-Cell Therapies
NewsFeb 27, 2026

[Comment] Safeguarding Genomic Integrity in Pluripotent Stem-Cell Therapies

Human pluripotent stem cells (hPSCs) are emerging as a transformative platform for Parkinson’s disease, with recent phase I/II trials showing successful engraftment of hESC‑ and iPSC‑derived dopaminergic neurons. Yet extensive data reveal that cultured hPSCs frequently acquire recurrent genetic lesions—most...

By The Lancet
[Comment] Language in Rare Disease: A Call for Systemic and Empathetic Action
NewsFeb 26, 2026

[Comment] Language in Rare Disease: A Call for Systemic and Empathetic Action

Globally, roughly 300 million individuals live with a rare disease, confronting isolation, diagnostic delays, and fragmented care. The Rare Diseases International–Lancet Commission argues that the language used by clinicians perpetuates stigma and hampers coordinated treatment. It calls for a systemic overhaul...

By The Lancet
[Comment] The Lancet Commission on Skin Health: Aligning with WHO Priorities
NewsFeb 26, 2026

[Comment] The Lancet Commission on Skin Health: Aligning with WHO Priorities

The Lancet Commission on Skin Health highlights that 4.7‑4.9 billion people worldwide suffer from skin diseases, placing these conditions among the leading causes of years lived with disability. The report quantifies skin disorders’ contribution at 1.79 % of global disability‑adjusted life‑years, underscoring...

By The Lancet
[Comment] Impact of Adding Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
NewsFeb 26, 2026

[Comment] Impact of Adding Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer

Adding androgen deprivation therapy (ADT) to definitive radiotherapy improves overall survival for men with high‑risk prostate cancer, but its benefit when combined with postoperative radiotherapy (PORT) after prostatectomy is less clear. Randomised trials such as GETUG‑AFU 16, SPPORT, and the RADICALS‑HD...

By The Lancet
[Comment] Oral GLP-1 Receptor Agonists: Competition for Efficacy and Tolerability
NewsFeb 26, 2026

[Comment] Oral GLP-1 Receptor Agonists: Competition for Efficacy and Tolerability

Oral GLP-1 receptor agonists have moved from injectable peptides to a tablet form, highlighted by oral semaglutide combined with the absorption enhancer SNAC. The formulation requires patients to fast overnight, take the dose with a small amount of water, and...

By The Lancet
[Comment] Managing Complex Antiretroviral Regimens
NewsFeb 25, 2026

[Comment] Managing Complex Antiretroviral Regimens

Switching antiretroviral therapy (ART) in people with HIV who have achieved sustained virological suppression is now a routine part of modern care. Advances in drug formulation, tolerability, and the rise of single‑tablet regimens have expanded treatment objectives beyond viral control....

By The Lancet
[Comment] Fundamental PEPFAR Reform Risks a Period of Structural Vulnerability in the HIV Response
NewsFeb 24, 2026

[Comment] Fundamental PEPFAR Reform Risks a Period of Structural Vulnerability in the HIV Response

One year after the 2025 policy upheaval, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) remains without congressional reauthorization, leaving its funding and implementation in flux. The program’s shift toward an “America First” bilateral strategy has re‑engineered coordination mechanisms...

By The Lancet
[Correspondence] Internet Shutdowns in Iran and the Right to Health
NewsFeb 23, 2026

[Correspondence] Internet Shutdowns in Iran and the Right to Health

In January 2026 Iran imposed a nationwide internet blackout that remains heavily filtered, coinciding with a violent crackdown on protesters and attacks on hospitals. The shutdown has crippled emergency medical coordination, tele‑medicine, and public‑health reporting, contributing to thousands of preventable...

By The Lancet
[Correspondence] Student Suicide Risk and Counselling in the Kurdistan Region of Iraq
NewsFeb 23, 2026

[Correspondence] Student Suicide Risk and Counselling in the Kurdistan Region of Iraq

A growing body of evidence shows that suicide and related behaviors are increasingly common among medical students worldwide, posing a serious challenge for education systems. The issue is especially acute in the Kurdistan Region of Iraq, where chronic crises exacerbate...

By The Lancet
[Correspondence] Why Ukraine's Energy Insecurity Is a Maternal Health Crisis
NewsFeb 19, 2026

[Correspondence] Why Ukraine's Energy Insecurity Is a Maternal Health Crisis

The Russian invasion has turned Ukraine’s energy grid into a weapon, leaving maternity hospitals without reliable power, heat, and medical equipment. Repeated strikes have caused 23 major attacks on health facilities this year, pushing premature‑birth rates to twice the national...

By The Lancet
[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease
NewsFeb 18, 2026

[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease

Adaptive deep brain stimulation (aDBS) introduces real‑time modulation of stimulation amplitude by tracking subthalamic beta activity, shifting Parkinson's therapy from fixed to physiomarker‑guided. Clinical trials report superior motor improvement, reduced stimulation‑related side effects, and markedly lower energy consumption compared with...

By The Lancet
[Clinical Rounds] A Multidisciplinary Management Approach to Cervical Cancer During Pregnancy
NewsFeb 18, 2026

[Clinical Rounds] A Multidisciplinary Management Approach to Cervical Cancer During Pregnancy

A 39‑year‑old gravida 3 woman presented at 10 weeks gestation with vaginal bleeding and a prior diagnosis of high‑grade squamous intraepithelial lesion (HSIL) that had not been followed up. Cervical cancer testing confirmed HSIL while the intrauterine pregnancy remained viable. The...

By The Lancet
[Comment] New Dietary Guidelines for Americans: A Recipe for Poorer Health
NewsFeb 16, 2026

[Comment] New Dietary Guidelines for Americans: A Recipe for Poorer Health

On Jan 7, 2026, HHS and USDA issued the 10th edition of the Dietary Guidelines for Americans. The new guidelines replace a decades‑long transparent, evidence‑based process with a conflicted, less rigorous framework. Critics argue the recommendations are contradictory and often lack scientific...

By The Lancet
[Correspondence] Dietary Evidence and the 2025–2030 US Guidelines
NewsFeb 16, 2026

[Correspondence] Dietary Evidence and the 2025–2030 US Guidelines

The U.S. Departments of Health and Human Services and Agriculture have released the 2025‑2030 Dietary Guidelines, introducing a revised pyramid that elevates animal‑based proteins, full‑fat dairy, and saturated fats. The correspondence questions whether this shift aligns with the broader global...

By The Lancet
[Articles] Lisocabtagene Maraleucel in Patients with Relapsed or Refractory Marginal Zone Lymphoma (TRANSCEND FL): Primary Analysis Results From the Global,...
NewsFeb 12, 2026

[Articles] Lisocabtagene Maraleucel in Patients with Relapsed or Refractory Marginal Zone Lymphoma (TRANSCEND FL): Primary Analysis Results From the Global,...

Lisocabtagene maraleucel, a CD19-directed CAR‑T therapy, demonstrated high overall response rates and durable remissions in patients with relapsed or refractory marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL trial. The global, multicohort, single‑arm study reported an 82 % overall response...

By The Lancet